U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275632) titled 'The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients' on Nov. 28.
Brief Summary: This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, ...